

Felipe CouÃ±ago

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1068590/publications.pdf>

Version: 2024-02-01

55
papers

465
citations

623734

14
h-index

839539

18
g-index

55
all docs

55
docs citations

55
times ranked

601
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions. World Journal of Clinical Oncology, 2019, 10, 318-339.	2.3	37
2	Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society). Lung Cancer, 2018, 118, 119-127.	2.0	27
3	Immunoradiotherapy as an Effective Therapeutic Strategy in Lung Cancer: From Palliative Care to Curative Intent. Cancers, 2020, 12, 2178.	3.7	25
4	Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC). Biomedicines, 2021, 9, 1247.	3.2	22
5	Clinical Applications of Molecular Biomarkers in Prostate Cancer. Cancers, 2020, 12, 1550.	3.7	21
6	The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases. European Urology Focus, 2021, 7, 241-244.	3.1	20
7	Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). Clinical and Translational Oncology, 2017, 19, 31-43.	2.4	19
8	Magnetic resonance imaging for prostate cancer before radical and salvage radiotherapy: What radiation oncologists need to know. World Journal of Clinical Oncology, 2017, 8, 305.	2.3	19
9	Role of 3.0T multiparametric MRI in local staging in prostate cancer and clinical implications for radiation oncology. Clinical and Translational Oncology, 2014, 16, 993-999.	2.4	18
10	Tumor staging using 3.0 T multiparametric MRI in prostate cancer: impact on treatment decisions for radical radiotherapy. SpringerPlus, 2015, 4, 789.	1.2	18
11	Role of 3T multiparametric magnetic resonance imaging without endorectal coil in the detection of local recurrent prostate cancer after radical prostatectomy: the radiation oncology point of view. Scandinavian Journal of Urology, 2015, 49, 360-365.	1.0	17
12	Phase III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for SMALL-CELL LUNG Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, S35-S36.	0.8	17
13	Changing the History of Prostate Cancer with New Targeted Therapies. Biomedicines, 2021, 9, 392.	3.2	16
14	GOECP/SEOR clinical recommendations for lung cancer radiotherapy during the COVID-19 pandemic. World Journal of Clinical Oncology, 2020, 11, 510-527.	2.3	16
15	Treatment Design and Rationale for a Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for SCLC: PREMER Trial on Behalf of the Oncologic Group for the Study of Lung Cancer/Spanish Radiation Oncology Group-Radiation Oncology Clinical Research Group. Clinical Lung Cancer, 2018, 19, e693-e697.	2.6	15
16	Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy. Cancers, 2021, 13, 4811.	3.7	14
17	Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges. Future Oncology, 2021, 17, 4011-4025.	2.4	10
18	Update on the treatment of metastatic renal cell carcinoma. World Journal of Clinical Oncology, 2022, 13, 1-8.	2.3	10

#	ARTICLE	IF	CITATIONS
19	Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions. Biomedicines, 2022, 10, 537.	3.2	9
20	Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish). Tj ETQq0 0 0 rgBT.4 Overlook 10 Tf 50	0.0	0
21	Evaluation of tumor recurrences after radical prostatectomy using 18F-Choline PET/CT and 3T multiparametric MRI without endorectal coil: a single center experience. Cancer Imaging, 2016, 16, 42.	2.8	7
22	Evidence-based recommendations of postoperative radiotherapy in lung cancer from Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). Clinical and Translational Oncology, 2016, 18, 331-341.	2.4	7
23	Recent developments in radiotherapy for small-cell lung cancer: a review by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). Clinical and Translational Oncology, 2017, 19, 1183-1192.	2.4	7
24	High-dose neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery in potentially-resectable stage IIIA-N2 NSCLC. A multi-institutional retrospective study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). Reports of Practical Oncology and Radiotherapy, 2020, 25, 447-455.	0.6	7
25	PET/TC con 68Ga-PSMA, importancia en la prÁctica hospitalaria. Visi3n del onc3logo radioterÁpico. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 302-314.	0.0	6
26	Extreme Hypofractionation with SBRT in Localized Prostate Cancer. Current Oncology, 2021, 28, 2933-2949.	2.2	6
27	Androgen Deprivation Therapy and Salvage Radiotherapy: Are We Missing Something?. European Urology, 2019, 76, 260-261.	1.9	5
28	SEORÁSBRT-SG stereotactic body radiation therapy consensus guidelines for non-spine bone metastasis. Clinical and Translational Oncology, 2022, 24, 215-226.	2.4	5
29	Neoadjuvant treatment in non-small cell lung cancer: New perspectives with the incorporation of immunotherapy. World Journal of Clinical Oncology, 2022, 13, 314-322.	2.3	5
30	GOECP/SEOR radiotherapy guidelines for small-cell lung cancer. World Journal of Clinical Oncology, 2021, 12, 115-143.	2.3	4
31	Deep diving in the PACIFIC: Practical issues in stage III non-small cell lung cancer to avoid shipwreck. World Journal of Clinical Oncology, 2020, 11, 898-917.	2.3	4
32	Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer. World Journal of Clinical Oncology, 2021, 12, 912-925.	2.3	4
33	Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial. Radiotherapy and Oncology, 2022, 172, 1-9.	0.6	4
34	Multiparametric MRI for prostate cancer: a national survey of patterns of practice among radiation oncologists in Spain. Clinical and Translational Oncology, 2018, 20, 1484-1491.	2.4	3
35	Importance of 68Ga-PSMA PET/CT in hospital practice. View of the radiation oncologist. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 302-314.	0.2	3
36	Impact of 68Ga-PSMA PET/CT in the treatment of prostate cancer: Initial experience in Spain. Reports of Practical Oncology and Radiotherapy, 2020, 25, 405-411.	0.6	3

#	ARTICLE	IF	CITATIONS
37	Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease. World Journal of Clinical Oncology, 2021, 12, 6-12.	2.3	3
38	Is there a place for optimizing thoracic radiotherapy in limited-stage small cell lung cancer after twenty years?. World Journal of Clinical Oncology, 2021, 12, 1-5.	2.3	3
39	Stereotactic body radiation therapy: A good dance partner of oligometastatic non-small cell lung cancer to the sound of SINDAS study. World Journal of Clinical Oncology, 2020, 11, 983-989.	2.3	3
40	Bone health and therapeutic agents in advanced prostate cancer. Frontiers in Bioscience, 2022, 27, 1.	2.1	3
41	Multiparametric magnetic resonance imaging-guided salvage radiotherapy in prostate cancer. Reports of Practical Oncology and Radiotherapy, 2019, 24, 472-480.	0.6	2
42	Metastatic hormone-sensitive prostate cancer: How should it be treated?. World Journal of Clinical Oncology, 2021, 12, 43-49.	2.3	2
43	GOECP/SEOR radiotherapy guidelines for thymic epithelial tumours. World Journal of Clinical Oncology, 2021, 12, 195-216.	2.3	2
44	New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer. World Journal of Clinical Oncology, 2021, 12, 983-999.	2.3	2
45	Single-fraction stereotactic ablative body radiation therapy for primary and metastatic lung tumor: A new paradigm?. World Journal of Clinical Oncology, 2022, 13, 101-115.	2.3	2
46	GOECP/SEOR clinical guidelines on radiotherapy for malignant pleural mesothelioma. World Journal of Clinical Oncology, 2021, 12, 581-608.	2.3	1
47	Postoperative radiotherapy in resected non-small cell lung cancer: The never-ending story. World Journal of Clinical Oncology, 2021, 12, 833-844.	2.3	1
48	Practice change in the management of metastatic urothelial carcinoma after ASCO 2020. World Journal of Clinical Oncology, 2020, 11, 976-982.	2.3	1
49	Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer. Journal of Clinical and Translational Research, 2021, 7, 185-198.	0.3	1
50	Current treatment landscape for oligometastatic non-small cell lung cancer. World Journal of Clinical Oncology, 2022, 13, 485-495.	2.3	1
51	Endorectal magnetic resonance imaging for risk classification of localized prostate cancer: Radiographic findings and influence on treatment decisions. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 477-478.	1.6	0
52	Letter by CouÃ±ago et al. regarding article â€œImpact of multiparametric magnetic resonance imaging on risk group assessment of patients with prostate cancer addressed to external beam radiation therapyâ€. European Journal of Radiology, 2016, 85, 2296-2297.	2.6	0
53	Response to: Low level evidence supporting the choice of optimal multimodality treatment approach in patients with stage IIIA NSCLC- ain't no mountain high enoughâ€. to keep me getting to you by Jeremic Branislav. Lung Cancer, 2018, 123, 174-175.	2.0	0
54	Adjuvant versus early salvage radiotherapy for prostate cancer patients: Time to move on. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 351-356.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Salvage local treatment for localized radio-recurrent prostate cancer: a narrative review and future perspectives. Future Oncology, 2021, 17, 4207-4219.	2.4	0